# US 2023/0142244 A1 · Compounds and combinations thereof for treating neurological and psychiatric conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0142244 A1
- Document ID: US20230142244A1
- Status: Published application
- Kind: A1
- Application number: 18/056,848
- Filed: 2022-11-18
- Published: 2023-05-11
- Earliest claimed: 2013-11-05
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20230142244A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 25/24: Antidepressants
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

## Claims

### Claim 1

A method of treating depression comprising: orally administering a dosage form to a human being in need thereof for at least 8 consecutive days, wherein the dosage form comprises a dextromethorphan and a fluoxetine, wherein the human being receives a total daily dose of about 30 mg to about 150 mg of the dextromethorphan; wherein the dextromethorphan and the fluoxetine are the only therapeutically active agents in the dosage form; wherein the human being is an extensive metabolizer of dextromethorphan; wherein on day 8, the human being has a dextromethorphan/dextrorphan plasma ratio of 0.3 or greater three hours after the dosage form is administered.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage form comprises about 20 mg to about 50 mg of the fluoxetine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the depression is major depressive disorder.

### Claim 4 (depends on 1)

The method of claim 1, wherein the depression is treatment resistant depression.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form provides immediate release of the dextromethorphan.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dosage form contains about 20 mg to about 50 mg of the dextromethorphan.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dosage form contains about 30 mg to about 60 mg of the dextromethorphan.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dosage form contains about 40 mg to about 50 mg of the dextromethorphan.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dosage form contains about 50 mg to about 70 mg of the dextromethorphan.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dosage form contains about 70 mg to about 100 mg of the dextromethorphan.

### Claim 12 (depends on 1)

The method of claim 1, wherein the dosage form contains about 45 mg of a dextromethorphan salt.

### Claim 13 (depends on 1)

The method of claim 1, wherein the dextromethorphan comprises a deuterium-modified dextromethorphan.

### Claim 14 (depends on 1)

The method of claim 1, wherein the dosage form is a capsule, a tablet, or a solution.

### Claim 15 (depends on 1)

The method of claim 1, wherein a dextromethorphan plasma level is increased as compared to administering the same amount of dextromethorphan alone.

### Claim 16 (depends on 1)

The method of claim 1, wherein the human being is converted to a poor metabolizer of dextromethorphan.

### Claim 17 (depends on 1)

The method of claim 1, wherein the dosage form further comprises a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

The method of claim 1, wherein the elimination half-life of dextromethorphan increases upon administration of the dosage form.
